Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153434 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
A Phase 2 study of Prader-Willi Syndrome, sponsored by Aardvark Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT05153434: Completed Phase 2 study of Prader-Willi Syndrome, sponsored by Aardvark Therapeutics.
NCT05153434 is a Phase 2 study of Prader-Willi Syndrome that has completed, run by Aardvark Therapeutics. The registered enrollment target is 19 participants, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05153434, a Phase 2 study of Prader-Willi Syndrome, has completed, sponsored by Aardvark Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
Primary Outcome
The incidence of treatment-emergent adverse events (TEAE) during the treatment period
Conditions Studied
Interventions
- DRUG ARD-101
Study Locations (2)
California
- Stanford University - Palo Alto
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2024-09-24 |
| Phase | Phase 2 |
What the finished NCT05153434 record still lists
NCT05153434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ARD-101 is the first listed.
NCT05153434 reports a single indexed study location in California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05153434 about?
NCT05153434 is a clinical study titled "A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome". A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
What is the current status of trial NCT05153434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2022-05-27. Estimated completion is 2024-09-24.
What conditions does trial NCT05153434 study?
This clinical trial studies the following conditions: Prader-Willi Syndrome.
What interventions are being tested in trial NCT05153434?
The interventions under investigation include: ARD-101 (DRUG).
Who is sponsoring clinical trial NCT05153434?
This trial is sponsored by Aardvark Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05153434 being conducted?
This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prader-Willi Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05153434's enrollment target sits among peer trials
19 12th of 16 higher than 5 of 16 other Prader-Willi Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prader-Willi Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
COMPLETED · Phase 2
-
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
COMPLETED · Phase 2
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI